Menu

Oncotarget Journal Cut from Medline

New papers from a cancer journal once named as a possibly predatory publication will no longer appear in the widely used research database.

Oct 26, 2017
Katarina Zimmer

ISTOCK, FACTORYTHMedline—a government biomedical research database—no longer lists new research articles from a cancer journal with a troubled reputation. 

Oncotarget, published by Impact Journals, was included in a now-inactive list of “possible predatory publishers” maintained by Jeffrey Beall, a librarian at the University of Colorado Denver. Beall has criticized Oncotarget’s peer review process as “questionable.”  

According to Retraction Watch, Oncotarget has issued “a handful” of recent retractions. This includes a paper published earlier this year on the genetics that underlie the development of cancer that was reportedly pulled due to “data errors” and “negligence.” Retraction Watch reports that the editor-in-chief, Mikhail Blagosklonny, considered retracting the research papers of Beall’s colleagues after the journal had been added to Beall’s list and Beall alerted the journal to potential problems with the publications. 

Medline is maintained by the U.S. National Library of Medicine, which gave no explanation as to why the journal was removed, according to Retraction Watch. However, papers published in Oncotarget will remain available on Pubmed, one of the most popular search tools for biomedical literature.

Beall coined the term predatory publishing to describe journals the exploit the open-access publishing model by collecting fees for publication that are well below those charged by legitimate open-access journals. Beall told The Scientist earlier this year, “They try to trick honest researchers, and sometimes they are successful.” 

Correction (November 15): Oncotarget’s legal representation alerted us to several inaccuracies, which we have clarified. The first paragraph now states that new articles are no longer listed in Medline. The third paragraph clarifies that it was Beall who had alerted Oncotarget to possible problems in his colleagues’ papers, and that Blagosklonny had considered retracting them. The Scientist regrets the errors.

Correction (November 17): The subheading to the article was clarified to also note that only new papers are de-listed from Medline and that Bealls list referred to journals as possibly predatory.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.